首页> 外文期刊>Technology in cancer research & treatment. >Macromolecular Changes in Nilotinib Resistant K562 Cells; an In vitro Study by Fourier Transform Infrared Spectroscopy
【24h】

Macromolecular Changes in Nilotinib Resistant K562 Cells; an In vitro Study by Fourier Transform Infrared Spectroscopy

机译:耐尼洛替尼的K562细胞的大分子变化;傅里叶变换红外光谱的体外研究

获取原文
       

摘要

Nilotinib is a second generation tyrosine kinase inhibitor which is used in both first and second line treatment of chronic myeloid leukemia (CML). In the present work, the effects of nilotinib resistance on K562 cells were investigated at the molecular level using Fourier transform infrared (FT-IR) spectroscopy. Human K562 CML cells were exposed to step-wise increasing concentrations of nilotinib, and sub-clones of K562 cells resistant to 50 nM nilotinib were generated and referred to as K562/NIL-50 cells. Antiproliferative effects of nilotinib were determined by XTT cell proliferation assay. Changes in macromolecules in parental and resistant cells were studied by FT-IR spectroscopy. Nilotinib resistance caused significant changes which indicated increases in the level of glycogen and membrane/lipid order. The amount of unsaturated lipids increased in the nilotinib resistant cells indicating lipid peroxidation. The total amount of lipids did not change significantly but the relative proportion of cholesterol and triglycerides altered considerably. Moreover, the transcriptional status decreased but metabolic turn-over increased as revealed by the FT-IR spectra. In addition, changes in the proteome and structural changes in both proteins and the nucleus were observed in the K562/NIL-50 cells. Protein secondary structural analyses revealed that alpha helix structure and random coil structure decreased, however, anti-parallel beta sheet structure, beta sheet structure and turns structure increased. These results indicate that the FT-IR technique provides a method for analyzing drug resistance related structural changes in leukemia and other cancer types.
机译:尼罗替尼是第二代酪氨酸激酶抑制剂,可用于慢性髓样白血病(CML)的一线和二线治疗。在当前的工作中,使用傅立叶变换红外光谱(FT-IR)在分子水平上研究了尼罗替尼耐药性对K562细胞的影响。将人K562 CML细胞暴露于逐步增加的尼罗替尼浓度下,并产生了对50 nM尼罗替尼具有抗性的K562细胞亚克隆,称为K562 / NIL-50细胞。尼洛替尼的抗增殖作用通过XTT细胞增殖试验确定。通过FT-IR光谱研究亲代和抗性细胞中大分子的变化。尼罗替尼耐药性引起显着变化,表明糖原水平和膜/脂质顺序增加。尼罗替尼耐药细胞中不饱和脂质的量增加,表明脂质过氧化。脂质的总量没有显着变化,但胆固醇和甘油三酸酯的相对比例发生了显着变化。此外,如FT-IR光谱所揭示的,转录状态降低了,但代谢周转增加了。另外,在K562 / NIL-50细胞中观察到蛋白质组的变化以及蛋白质和核的结构变化。蛋白质二级结构分析显示α螺旋结构和无规卷曲结构降低,但是反平行β折叠结构,β折叠结构和匝结构增加。这些结果表明,FT-IR技术提供了一种用于分析与白血病和其他癌症类型相关的耐药性结构变化的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号